NO20022820L - Terapeutisk anvendelige syntetiske oligonukleotider - Google Patents

Terapeutisk anvendelige syntetiske oligonukleotider

Info

Publication number
NO20022820L
NO20022820L NO20022820A NO20022820A NO20022820L NO 20022820 L NO20022820 L NO 20022820L NO 20022820 A NO20022820 A NO 20022820A NO 20022820 A NO20022820 A NO 20022820A NO 20022820 L NO20022820 L NO 20022820L
Authority
NO
Norway
Prior art keywords
synthetic oligonucleotides
therapeutically useful
useful synthetic
induction
group
Prior art date
Application number
NO20022820A
Other languages
English (en)
Other versions
NO330508B1 (no
NO20022820D0 (no
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of NO20022820D0 publication Critical patent/NO20022820D0/no
Publication of NO20022820L publication Critical patent/NO20022820L/no
Publication of NO330508B1 publication Critical patent/NO330508B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20022820A 1999-12-13 2002-06-13 Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav. NO330508B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17032599P 1999-12-13 1999-12-13
US22892500P 2000-08-29 2000-08-29
PCT/CA2000/001467 WO2001044465A2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Publications (3)

Publication Number Publication Date
NO20022820D0 NO20022820D0 (no) 2002-06-13
NO20022820L true NO20022820L (no) 2002-08-08
NO330508B1 NO330508B1 (no) 2011-05-09

Family

ID=26865979

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022820A NO330508B1 (no) 1999-12-13 2002-06-13 Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav.

Country Status (18)

Country Link
US (2) US7157436B2 (no)
EP (2) EP1238070B1 (no)
JP (1) JP4772245B2 (no)
KR (1) KR100829646B1 (no)
CN (2) CN101491536B (no)
AT (2) ATE455851T1 (no)
AU (1) AU785212B2 (no)
CA (1) CA2393808A1 (no)
CZ (1) CZ20022372A3 (no)
DE (2) DE60036019T2 (no)
DK (2) DK1867718T3 (no)
ES (2) ES2340807T3 (no)
HU (1) HUP0300627A3 (no)
IL (2) IL150196A0 (no)
MX (1) MXPA02005842A (no)
NO (1) NO330508B1 (no)
PT (1) PT1238070E (no)
WO (1) WO2001044465A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
AU775412B2 (en) 1999-04-08 2004-07-29 Advanced Cancer Therapeutics, Inc. Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CA2393808A1 (en) * 1999-12-13 2001-06-21 Bioniche Life Sciences Inc. Anti-cancer synthetic oligonucleotides
AU6886301A (en) 2000-08-29 2002-03-13 Bioniche Life Sciences Inc Modulation of fas and fasl expression
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
KR100943567B1 (ko) 2001-08-17 2010-02-22 바이오니취 라이프 사이언시즈 인코포레이티드 세포사멸-유도성 포스포디에스테르올리고뉴클레오타이드의 입체구조-활성 관계성
CA2462425A1 (en) 2001-10-03 2003-04-10 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
JP2006515266A (ja) 2002-04-22 2006-05-25 バイオニケ ライフ サイエンシーズ インコーポレイテッド オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004103301A2 (en) * 2003-05-16 2004-12-02 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
CA2598992A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
CA2600440A1 (en) * 2005-03-09 2006-09-21 Baylor College Of Medicine Direct reversal of the suppressive function of cd4+ regulatory t cells via toll-like receptor 8 signaling
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
EP2396408B1 (en) * 2009-02-12 2017-09-20 CuRNA, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
WO2011008305A1 (en) * 2009-07-15 2011-01-20 Enzon Pharmaceuticals, Inc. Rna antagonists targeting gli2 for the treatment of leukemia
JP6155533B2 (ja) * 2012-02-28 2017-07-05 国立大学法人東京農工大学 Ｔｄｐ−４３細胞内存在量関連疾患の認定方法
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
WO2023122762A1 (en) * 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
FR2160326B1 (no) * 1971-11-19 1975-02-07 Anvar
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
US4010257A (en) * 1973-02-23 1977-03-01 Burroughs Wellcome Co. Biological extracts
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
WO1992014842A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US6475795B1 (en) * 1991-07-03 2002-11-05 Meditech Research, Ltd. Use of hyaluronan in gene therapy
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
BR9406496A (pt) * 1993-01-29 1996-01-02 Vetrepharm Inc Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) * 1994-05-25 1997-07-16 海布里登公司 具有抗巨细胞病毒活性的寡核苷酸
JPH10505233A (ja) * 1994-08-30 1998-05-26 コモンウェルス サイエンティフック アンド インダストリアル リサーチ オーガニゼーション シルコウイルス由来の植物転写調節因子
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (no) * 1995-02-14 1998-05-30 Bioniche Inc
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
AU708096B2 (en) * 1995-11-21 1999-07-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for IL-8 and IL-8 receptor
IT1277025B1 (it) 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
CA2255822A1 (en) * 1996-05-20 1997-11-27 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Oligonucleotides which specifically bind retroviral nucleocapsid proteins
JP4335435B2 (ja) * 1997-08-05 2009-09-30 バイオニケ ライフ サイエンシーズ インコーポレイテッド 細胞増殖および細胞死を調節する組成物および方法
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
AP1775A (en) * 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
CA2393808A1 (en) * 1999-12-13 2001-06-21 Bioniche Life Sciences Inc. Anti-cancer synthetic oligonucleotides
DK1250152T3 (da) * 1999-12-28 2013-08-26 Bioniche Urology Ip Inc Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
CA2462425A1 (en) * 2001-10-03 2003-04-10 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
JP2006515266A (ja) * 2002-04-22 2006-05-25 バイオニケ ライフ サイエンシーズ インコーポレイテッド オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用

Also Published As

Publication number Publication date
CZ20022372A3 (cs) 2002-11-13
AU1847901A (en) 2001-06-25
EP1867718A2 (en) 2007-12-19
ATE455851T1 (de) 2010-02-15
CN101491536A (zh) 2009-07-29
US20010041681A1 (en) 2001-11-15
IL150196A0 (en) 2002-12-01
HUP0300627A2 (hu) 2004-06-28
CN1433469A (zh) 2003-07-30
DK1238070T3 (da) 2007-12-03
ATE370231T1 (de) 2007-09-15
KR20020079752A (ko) 2002-10-19
DK1867718T3 (da) 2010-04-12
EP1238070B1 (en) 2007-08-15
DE60036019D1 (de) 2007-09-27
NO330508B1 (no) 2011-05-09
DE60043759D1 (de) 2010-03-11
EP1867718B1 (en) 2010-01-20
WO2001044465A3 (en) 2001-11-29
JP2003517041A (ja) 2003-05-20
NO20022820D0 (no) 2002-06-13
JP4772245B2 (ja) 2011-09-14
CN100445380C (zh) 2008-12-24
US7157436B2 (en) 2007-01-02
US20070213291A1 (en) 2007-09-13
WO2001044465A2 (en) 2001-06-21
ES2288883T3 (es) 2008-02-01
EP1867718A3 (en) 2008-04-02
EP1238070A2 (en) 2002-09-11
DE60036019T2 (de) 2008-05-29
IL150196A (en) 2009-06-15
KR100829646B1 (ko) 2008-05-16
AU785212B2 (en) 2006-11-09
CN101491536B (zh) 2012-07-04
HUP0300627A3 (en) 2005-11-28
MXPA02005842A (es) 2003-10-14
CA2393808A1 (en) 2001-06-21
PT1238070E (pt) 2007-11-06
ES2340807T3 (es) 2010-06-09

Similar Documents

Publication Publication Date Title
DK1238070T3 (da) Terapeutisk anvendelige syntetiske oligonucleotider
EP0666923A4 (en) TARGETED PROVISION OF POLY- OR OLIGONUCLEOTIDES IN CELLS.
HK1057553A1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents forthe inhibition of the cell proliferation.
GB2340121B (en) Delivery system
GB2363874B (en) Bioinformatic transaction scheme
IL173888A0 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
AU2001248331A1 (en) Medicaments against viral diseases
MXPA01011086A (es) Sistema de transferencia por correa.
MXPA03009132A (es) Alquilhidroxamatos triciclicos, su preparacion y su uso como inhibidores de la proliferacion de celulas.
ZA200108847B (en) 1-Amino triazoloc4,3-a! Quinazoline-5-ones and or -5-thiones inhibiting phosphodiesterase IV
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
ZA200005186B (en) Thermal Shock-resistant ceramic article.
GB9903718D0 (en) Radiant burner
GB9807114D0 (en) Novel process
HK1078781A1 (en) Processes for preparing 1,3-dioxolane nucleosides
HK1041598A1 (en) Formulation with an improved therapeutic range, containing nucleotide synthesis in hibitors.
PH31659A (en) Therapeutic nucleotides.
MXPA04002530A (es) Oligonucleotidos de treitilenglicol colesteril terapeuticamente utiles.
IT1318377B1 (it) Articolo di ornamento della persona dotato di sistema per il cambio diornamento.
EP1226280A4 (en) GENETIC SEQUENCES ASSOCIATED WITH THE PROLIFERATION AND PATHOLOGIES OF NEURONAL CELLS
GB9921938D0 (en) Target for antiviral therapy
ITMI920892A1 (it) Selezione genica in vitro mediante vettori ad rna
ITMI991513A0 (it) Piastra radiante per panificazione
GB0000683D0 (en) Antiviral treatment
ITMO990054A0 (it) Gruppo per la regolazione dell'alimentazione di un impianto di riscald amento.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees